Multiplex Real-time PCR methods for diagnosing Lumpy skin disease virus
A kit using specific primer sets for RT-PCR efficiently differentiates and diagnoses CPV and LSDV strains, addressing the challenge of strain differentiation and ensuring rapid, accurate diagnosis.
Patent Information
- Application Number
- KR1020240044308
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-04-01
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2044-04-01
AI Technical Summary
Current methods struggle to differentiate between Capripoxvirus (CPV), Lumpy Skin Disease Virus (LSDV), and their vaccine-derived recombinant strains, leading to challenges in diagnosing and managing outbreaks effectively.
A kit comprising specific primer sets (SEQ ID NOs 1-20) for RT-PCR that can simultaneously detect and differentiate between CPV, LSDV, vaccine strains, and vaccine-derived recombinant field strains, ensuring high sensitivity and specificity without non-specific amplification.
The kit enables rapid, accurate differentiation and diagnosis of CPV, LSDV, and their strains within an hour, effectively managing outbreaks by identifying variant viruses and preventing cross-reactivity with other bovine diseases.
Smart Images

Figure 112024036247620-PAT00084_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a kit for detecting Lumpy Skin Virus, and more specifically, to a detection kit capable of simultaneously differentiating and detecting Capripoxvirus (CPV) and Lumpy Skin Virus (LSDV), and capable of simultaneously differentiating and detecting field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy Skin Virus. Background Technology
[0002] Lumpy skin disease virus (LSDV) is a double-stranded DNA virus that causes lumpy skin disease in cattle, belonging to the Poxviridae family ( Poxviridae Caprifoxi virus genus of the family Capripoxvirus It belongs to the Genus. Lumpy skin disease is a viral disease that infects cattle and water buffaloes, primarily transmitted by blood-sucking insects such as mosquitoes, flies, and ticks. It causes numerous small nodules on the skin and mucous membranes of infected cattle and is known to cause symptoms such as loss of appetite, weakness, excessive salivation, increased secretions from the eyes and nose, and enlarged lymph nodes, as well as severe economic damage including a sharp decline in milk production, skin damage, miscarriage, and infertility in bulls.
[0003] Lumpy skin first appeared in Korea in October 2023, resulting in confirmed cases at approximately 107 farms and causing severe economic losses to farms. However, thanks to the efforts of relevant agencies and organizations, such as quarantine measures and vaccinations, there have been no additional outbreaks since November 20, 2023.
[0004] As of November 10, 2023, vaccination of 4,075,000 cattle across 93,944 farms nationwide has been completed, and since most other countries where Lumpy Skin is prevalent are also currently using preventive vaccines, there is a need for a testing method that can not only distinguish between field strains and vaccine strains but also, more recently, differentiate between vaccine-derived recombinant field strains (vaccine-like recombinant strain, cluster 2.5).
[0005] Also, Caprifox virus ( Capripoxvirus The genus CPV belongs to the family Poxviridae. Poxviridae It belongs to the family CPV, which includes three species: sheeppox virus (SPV), goatpox virus (GTPV), and lumpy skin virus (LSDV) (Wolff, Janika, et al. Viruses 12.10 (2020): 1098.), and the genomes of SPPV and GTPV are very similar to the genome of LSDV, sharing 97% of nucleotide identity (Tulman, ER, et al. Journal of virology 76.12 (2002): 6054-6061.). Therefore, differential diagnosis of LSDV from SPPV and GTPV, which are viruses of the CPV genus, is required. The problem to be solved
[0006] Accordingly, the inventors performed detection on a sample using a first primer set capable of detecting Capripoxvirus (CPV), a second primer set capable of detecting Lumpy Skin Disease Virus (LSDV), and a third primer set, and confirmed that it is possible to simultaneously differentiate between Capripoxvirus (CPV) and Lumpy Skin Disease Virus (LSDV), exhibits excellent detection sensitivity, and does not cause non-specific amplification of major viruses that can infect cattle, thus confirming that the detection performance is excellent.
[0007] Accordingly, the inventors performed detection on a sample using a second primer set capable of detecting both the vaccine strain and the vaccine-derived recombinant field strain of Lumpy Skin Virus (LSDV), a third primer set capable of detecting the LSDV field strain, and a fourth primer set capable of detecting the LSDV vaccine strain. As a result, they confirmed that the detection performance is excellent, as it can simultaneously differentiate and diagnose the field strain, vaccine strain, and vaccine-derived recombinant field strain of Lumpy Skin Virus (LSDV), exhibits excellent detection sensitivity, and does not cause non-specific amplification of other major bovine viruses.
[0008] Accordingly, the inventors performed detection on a sample using a third primer set capable of detecting the field strain of Lumpy Skin Virus (LSDV), a fourth primer set capable of detecting the vaccine strain of LSDV, and a fifth primer set capable of detecting both the field strain of LSDV and the vaccine-derived recombinant field strain. As a result, they confirmed that the detection performance is excellent, as the field strain, vaccine strain, and vaccine-derived recombinant field strain of Lumpy Skin Virus (LSDV) can be simultaneously differentiated and diagnosed, exhibiting excellent detection sensitivity, and no non-specific amplification of other viruses of major bovine diseases occurs.
[0009] Accordingly, the objective of the present invention is to provide a composition for detecting a lumpy skin virus comprising one or more primer sets selected from the group consisting of: a first primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 1 and a reverse primer with a nucleotide sequence of SEQ ID NO. 2; a second primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 4 and a reverse primer with a nucleotide sequence of SEQ ID NO. 5; a third primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 7 and a reverse primer with a nucleotide sequence of SEQ ID NO. 8; a fourth primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 16 and a reverse primer with a nucleotide sequence of SEQ ID NO. 17; and a fifth primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 19 and a reverse primer with a nucleotide sequence of SEQ ID NO. 20.
[0010] Another objective of the present invention is to provide a kit for detecting Lumpy Skin Virus comprising one or more primer sets selected from the group consisting of: a first primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 1 and a reverse primer with a nucleotide sequence of SEQ ID NO. 2; a second primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 4 and a reverse primer with a nucleotide sequence of SEQ ID NO. 5; a third primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 7 and a reverse primer with a nucleotide sequence of SEQ ID NO. 8; a fourth primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 16 and a reverse primer with a nucleotide sequence of SEQ ID NO. 17; and a fifth primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 19 and a reverse primer with a nucleotide sequence of SEQ ID NO. 20.
[0011] Another objective of the present invention is to provide a method for providing information for diagnosing a lumpy skin virus infection, comprising an amplification step of amplifying a target nucleic acid from a sample separated from a specimen, using a composition for detecting lumpy skin virus comprising one or more primer sets selected from the group consisting of: a first primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 1 and a reverse primer with a nucleotide sequence of SEQ ID NO. 2; a second primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 4 and a reverse primer with a nucleotide sequence of SEQ ID NO. 5; a third primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 7 and a reverse primer with a nucleotide sequence of SEQ ID NO. 8; a fourth primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 16 and a reverse primer with a nucleotide sequence of SEQ ID NO. 17; and a fifth primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 19 and a reverse primer with a nucleotide sequence of SEQ ID NO. 20.
[0012] Another objective of the present invention is to use one or more primer sets selected from the group consisting of: a first primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 1 and a reverse primer with a nucleotide sequence of SEQ ID NO. 2; a second primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 4 and a reverse primer with a nucleotide sequence of SEQ ID NO. 5; a third primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 7 and a reverse primer with a nucleotide sequence of SEQ ID NO. 8; a fourth primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 16 and a reverse primer with a nucleotide sequence of SEQ ID NO. 17; and a fifth primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 19 and a reverse primer with a nucleotide sequence of SEQ ID NO. 20 for detecting Lumpy Skin Virus. means of solving the problem
[0013] The present invention relates to a kit for detecting Lumpy skin disease virus (LSDV). The detection kit according to the present invention can simultaneously detect Caprifox virus (CPV) and Lumpy skin virus, and can simultaneously differentiate and detect field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy skin virus.
[0014] The inventors performed detection on a sample using a first primer set capable of detecting Caprifox virus (CPV), a second primer set capable of detecting Lumpy Skin Virus (LSDV), and a third primer set, and confirmed that the detection performance is excellent, as it can simultaneously differentiate between Caprifox virus (CPV) and Lumpy Skin Virus (LSDV), exhibits excellent detection sensitivity, and does not cause non-specific amplification of other viruses of major bovine diseases.
[0015] In addition, the inventors performed detection on a sample using a second primer set capable of detecting both the vaccine strain and the vaccine-derived recombinant field strain of Lumpy Skin Virus (LSDV), a third primer set capable of detecting the LSDV field strain, and a fourth primer set capable of detecting the LSDV vaccine strain. As a result, they confirmed that the detection performance is excellent, as the field strain, vaccine strain, and vaccine-derived recombinant field strain of Lumpy Skin Virus (LSDV) can be simultaneously differentiated and diagnosed, exhibiting excellent detection sensitivity, and no non-specific amplification of other viruses of major bovine diseases occurs.
[0016] In addition, the inventors performed detection on a sample using a third primer set capable of detecting LSDV field strains, a fourth primer set capable of detecting LSDV vaccine strains, and a fifth primer set capable of detecting both field strains and vaccine-derived recombinant field strains of Lumpy Skin Virus (LSDV). As a result, they confirmed that the detection performance is excellent, as it can simultaneously differentiate and diagnose field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy Skin Virus (LSDV), exhibits excellent detection sensitivity, and does not cause non-specific amplification of other viruses of major bovine diseases.
[0017] The present invention will be described in more detail below.
[0018] One aspect of the present invention comprises a first primer set including a forward primer having the nucleotide sequence of SEQ ID NO. 1 and a reverse primer having the nucleotide sequence of SEQ ID NO. 2;
[0019] A second primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 4 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 5;
[0020] A third primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 7 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 8;
[0021] A fourth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 16 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 17; and
[0022] A fifth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 19 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 20;
[0023] The present invention relates to a composition for detecting lumpy skin virus comprising one or more primer sets selected from the group consisting of
[0024] In the present invention, the term "primer" refers to a single-stranded oligonucleotide sequence complementary to the nucleic acid strand to be amplified, and can serve as a starting point for the synthesis of a primer extension product. The primer can initiate DNA synthesis in the presence of a reagent for a polymerization reaction (i.e., DNA polymerase or reverse transcriptase) and four different nucleoside triphosphates at an appropriate buffer solution and temperature.
[0025] In the present invention, the first primer set may specifically amplify the LSDV LW068 gene, the second primer set may specifically amplify the LSDV LW011 gene, the third primer set may specifically amplify the LSDV LW126 gene, the fourth primer set may specifically amplify the LSDV LW144 gene, and the fifth primer set may specifically amplify the LSDV LW133 gene.
[0026] In the present invention, the LSDV LW068 gene is a gene encoding Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1, the LSDV LW011 gene is a gene encoding CC chemokine receptor-like protein, the LSDV LW126 gene is a gene encoding putative EEV glycoprotein, the LSDV LW144 gene is a gene encoding kelch-like protein, and the LSDV LW133 gene is a gene encoding DNA ligase.
[0027] In addition, in the present invention, the first primer set can detect Caprifox virus (CPV) in common, the second primer set can detect LSDV vaccine strains and LSDV vaccine-derived recombinant field strains in common, the third primer set can detect LSDV field strains, and when the second primer set and the third primer set are used together, Lumpy Skin Virus (LSDV) can be detected in common, the fourth primer set can detect LSDV vaccine strains, and the fifth primer set can detect LSDV field strains and LSDV vaccine-derived recombinant field strains in common.
[0028] In the present invention, the composition comprises a first primer set including a forward primer consisting of the nucleotide sequence of SEQ ID NO. 1 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 2; and
[0029] A second primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 4 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 5,
[0030] A third primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 7 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 8,
[0031] A fourth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 16 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 17, and
[0032] A fifth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 19 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 20.
[0033] One or more primer sets selected from the group consisting of; and
[0034] It simultaneously detects Capripoxvirus (CPV) and Lumpy Skin virus.
[0035] In the present invention, the composition may simultaneously detect caprifox virus (CPV) and lumpy skin virus (LSDV). When all of the first, second, and third primer sets are included, it is possible to simultaneously diagnose caprifox virus (CPV) and lumpy skin virus (LSDV).
[0036] In the present invention, the caprifox virus may be one or more selected from the group consisting of sheeppox virus (SPPV) and goatpox virus (GTPV). When all of the first, second, and third primer sets are included, it is possible to simultaneously differentiate and diagnose Lumpy Skin Virus (LSDV) from sheeppox virus (SPPV) and goatpox virus (GTPV).
[0037] In the present invention, the above composition is
[0038] A second primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 4 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 5;
[0039] A third primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 7 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 8;
[0040] A fourth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 16 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 17; and
[0041] A fifth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 19 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 20;
[0042] It includes two or more primer sets selected from the group consisting of,
[0043] Simultaneous differential detection of two or more types selected from a group consisting of field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy Skin Virus.
[0044] In the present invention, the composition may simultaneously differentiate and detect field strains, vaccine strains, and vaccine-derived recombinant field strains of the Lumpy Skin virus. Vaccination of 4,075,000 cattle in 93,944 farms nationwide has been completed, and as most other countries where Lumpy Skin is prevalent are currently using attenuated vaccines, differential diagnosis of field strains, vaccine strains, and vaccine-derived recombinant field strains is required.
[0045] In addition, vaccine-derived recombinant field strains are variant viruses created by mixing two or more types of viral genes, such as vaccine strains and field strains. Since existing methods for distinguishing vaccine strains and field strains based on GPCR (G protein-coupled receptor) genes have limitations in that vaccine-derived recombinant field strains cannot be identified as field strains, it is necessary to develop a method to distinguish vaccine-derived recombinant field strains from existing field strains and vaccine strains using differentiated target genes.
[0046] The present invention has the advantage of being able to simultaneously differentiate and diagnose field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy Skin Virus with a rapid testing time of less than one hour through a single RT-PCR (real-time PCR). When all of the second, third, and fourth primer sets are included, or when all of the third, fourth, and fifth primer sets are included, it is possible to simultaneously differentiate and diagnose field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy Skin Virus.
[0047] In the present invention, the field strain may be an LSDV classical field strain and may belong to Cluster 1.2 or Clade 1.2, the vaccine strain may be an LSDV kneeling vaccine strain and may belong to Cluster 1.1 or Clade 1.1, and the vaccine-derived recombinant field strain may be an LSDV vaccine-like recombinant strain and may belong to Cluster 2.5 or Clade 2.5 (Breman, Floris C., et al. "Lumpy skin disease virus genome sequence analysis: putative spatio-temporal epidemiology, single gene versus whole genome phylogeny and genomic evolution." Viruses 15.7 (2023): 1471. See reference).
[0048] In the present invention, the composition for detecting the lumpy skin virus comprises a sixth primer set including a forward primer consisting of the nucleotide sequence of SEQ ID NO. 10 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 11; and
[0049] It may additionally include one or more primer sets selected from the group consisting of a seventh primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 13 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 14.
[0050] In the present invention, the sixth primer set may specifically amplify the bovine GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene and may be for detecting bovine-derived samples, and in one embodiment of the present invention, it is referred to as a bovine endogenous internal positive control primer, endogenous IPC, or endo IPC.
[0051] In the present invention, the seventh primer set may specifically amplify an oligo designed within a random sequence and may be used to confirm whether the PCR reaction is normal. In one embodiment of the present invention, it is referred to as an exogenous internal positive control (IPC) primer, an exogenous IPC, or an exo IPC. When using an exogenous IPC primer, it is possible to confirm whether the qPCR reaction is functioning normally without interfering with LSDV detection.
[0052] In the present invention, the term "probe" refers to a nucleic acid fragment corresponding to several to hundreds of bases that can specifically bind to DNA or RNA, and may be manufactured in the form of an oligonucleotide probe, a single-stranded DNA probe, a double-stranded DNA probe, or an RNA probe.
[0053] In the present invention, the composition may additionally include one or more probes selected from the group consisting of a probe with the nucleotide sequence of SEQ ID NO. 3, a probe with the nucleotide sequence of SEQ ID NO. 6, a probe with the nucleotide sequence of SEQ ID NO. 9, a probe with the nucleotide sequence of SEQ ID NO. 18, and a probe with the nucleotide sequence of SEQ ID NO. 21.
[0054] In the present invention, the composition may additionally include one or more probes selected from the group consisting of a probe with the nucleotide sequence of SEQ ID NO. 12 and a probe with the nucleotide sequence of SEQ ID NO. 15.
[0055] In the present invention, the probe may additionally include a reporter or a quencher.
[0056] In the present invention, the reporter may be conjugated to the 5' end of the probe, and may be FAM (6-carboxyfluorescein), HEX (2',4',5',7'-tetrachloro-6-carboxy-4,7-dichlorofluorescein), Cy5 (Cyanine5), Texas Red (TxR), fluorescein, fluorescein chlorotriazinyl, rhodamine green, rhodamine red, tetramethylrhodamine, FITC (fluorescein isothiocyanate), Oregon Green, Alexa Fluor, JOE (6-Carboxy-4',5'-Dichloro-2',7'-Dimethoxyfluorescein), ROX (6-Carboxyl-X-Rhodamine), It may be one or more selected from the group consisting of TET (Tetrachloro-Fluorescein), TRITC (tertramethylrodamine isothiocyanate), TAMRA (6-carboxytetramethyl-rhodamine), NED (N-(1-Naphthyl) ethylenediamine), cyanine series dyes and thiadicarbocyanine, but is not limited thereto.
[0057] In the present invention, the quencher may be attached to the 3' end of the probe and may be one or more selected from the group consisting of TAMRA (6-carboxytetramethyl-rhodamine), BHQ1 (black hole quencher 1), BHQ2 (black hole quencher 2), BHQ3 (black hole quencher 3), NFQ (nonfluorescent quencher), dabcyl, Eclipse, DDQ (Deep Dark Quencher), Blackberry Quencher, Iowa black, and MGB (minor groove binder), but is not limited thereto.
[0058] In one embodiment of the present invention, the probe composed of the nucleotide sequence of SEQ ID NO. 6 and the probe composed of the nucleotide sequence of SEQ ID NO. 9 may include the same reporter.
[0059] In the present invention, if a variant having biologically equivalent activity is considered, the nucleotide sequences of SEQ ID NOs 1 to 21 may be interpreted as including nucleotide sequences that exhibit substantial identity therewith.
[0060] In the present invention, the term "substantial identity" means that when an amino acid sequence of a specific sequence number and any other sequence are aligned to correspond as much as possible and the aligned sequence is analyzed using an algorithm commonly used in the art, it exhibits at least 60% homology, at least 70% homology, at least 80% homology, or at least 90% homology.
[0061] Alignment methods for comparing sequences are known in the art. For example, sequence analysis programs such as blastp, blastx, tblastn, and tblastx can be used on the internet through the NCBI Basic Local Alignment Search Tool (BLAST).
[0062] In the present invention, the composition for detecting the lumpy skin virus may additionally include a reaction amplification mixture, for example, a polymerase, dNTPs, a reaction buffer, etc.
[0064] Another aspect of the present invention comprises a first primer set including a forward primer consisting of the nucleotide sequence of SEQ ID NO. 1 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 2;
[0065] A second primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 4 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 5;
[0066] A third primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 7 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 8;
[0067] A fourth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 16 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 17; and
[0068] A fifth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 19 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 20;
[0069] The present invention relates to a kit for detecting Lumpy skin disease virus (LSDV) comprising one or more primer sets selected from a group consisting of
[0070] In the present invention, the kit is
[0071] A first primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 1 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 2; and
[0072] A second primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 4 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 5,
[0073] A third primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 7 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 8,
[0074] A fourth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 16 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 17, and
[0075] A fifth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 19 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 20.
[0076] One or more primer sets selected from the group consisting of; and
[0077] It simultaneously detects Capripoxvirus (CPV) and Lumpy Skin virus.
[0078] In the present invention, the kit may simultaneously detect Capripoxvirus (CPV) and Lumpy Skin Virus.
[0079] In the present invention, the caprifox virus may be one or more selected from the group consisting of sheeppox virus (SPPV) and goatpox virus (GTPV).
[0080] In the present invention, the kit is
[0081] A second primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 4 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 5;
[0082] A third primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 7 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 8;
[0083] A fourth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 16 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 17; and
[0084] A fifth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 19 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 20;
[0085] It includes two or more primer sets selected from the group consisting of,
[0086] Simultaneous differential detection of two or more types selected from a group consisting of field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy Skin Virus.
[0087] In the present invention, the kit may simultaneously detect field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy Skin Virus.
[0088] In the present invention, the kit may additionally include one or more probes selected from the group consisting of a probe with the nucleotide sequence of SEQ ID NO. 3, a probe with the nucleotide sequence of SEQ ID NO. 6, a probe with the nucleotide sequence of SEQ ID NO. 9, a probe with the nucleotide sequence of SEQ ID NO. 18, and a probe with the nucleotide sequence of SEQ ID NO. 21.
[0089] In the present invention, the probe may additionally include a reporter or a quencher.
[0090] In the present invention, the kit may include a premix (A) comprising a first, second, and third primer set.
[0091] In the present invention, the premix (A) may additionally include a probe consisting of the nucleotide sequence of SEQ ID NO. 3, a probe consisting of the nucleotide sequence of SEQ ID NO. 6, and a probe consisting of the nucleotide sequence of SEQ ID NO. 9.
[0092] In the present invention, the premix (A) may additionally include a sixth and seventh primer set.
[0093] In the present invention, the premix (A) may additionally include a probe consisting of the nucleotide sequence of SEQ ID NO. 12 and a probe consisting of the nucleotide sequence of SEQ ID NO. 15.
[0094] In the present invention, the premix (A) can simultaneously detect caprifoxic virus (CPV) and lumpy skin virus (LSDV), or can simultaneously detect lumpy skin virus (LSDV) from sheep pox virus (SPPV) and goat pox virus (GTPV).
[0095] In the present invention, the kit may include a premix (B) comprising a second, third, and fourth primer set.
[0096] In the present invention, the premix (B) may additionally include a probe consisting of the nucleotide sequence of SEQ ID NO. 6, a probe consisting of the nucleotide sequence of SEQ ID NO. 9, and a probe consisting of the nucleotide sequence of SEQ ID NO. 18.
[0097] In the present invention, the premix (B) may additionally include a sixth or seventh primer set.
[0098] In the present invention, the premix (B) may additionally include a probe consisting of the nucleotide sequence of SEQ ID NO. 12 or a probe consisting of the nucleotide sequence of SEQ ID NO. 15.
[0099] In the present invention, the premix (B) is capable of simultaneously distinguishing and detecting field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy Skin Virus.
[0100] In the present invention, the kit may include a premix (C) comprising a third, fourth, and fifth primer set.
[0101] In the present invention, the premix (C) may additionally include a probe consisting of the nucleotide sequence of SEQ ID NO. 9, a probe consisting of the nucleotide sequence of SEQ ID NO. 18, and a probe consisting of the nucleotide sequence of SEQ ID NO. 21.
[0102] In the present invention, the premix (C) may additionally include a sixth or seventh primer set.
[0103] In the present invention, the premix (C) may additionally include a probe consisting of the nucleotide sequence of SEQ ID NO. 12 or a probe consisting of the nucleotide sequence of SEQ ID NO. 15.
[0104] In the present invention, the premix (C) is capable of simultaneously distinguishing and detecting field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy Skin Virus.
[0105] In the present invention, the premix (C) can simultaneously differentiate and detect the vaccine strain and the vaccine-derived recombinant field strain even in cases of simultaneous infection with the vaccine strain and the vaccine-derived recombinant field strain. In the present invention, the premix (C) can detect breakthrough infection of the vaccine-derived recombinant field strain in vaccinated individuals. The individual is a cattle.
[0106] In the present invention, the kit may include the premix (A) and the premix (B), include the premix (A) and the premix (C), or include the premix (A), the premix (B), and the premix (C).
[0107] Since the kit for detecting the Lumpy Skin Virus of the present invention includes a primer set identical and similar to the composition for detecting the Lumpy Skin Virus of another embodiment of the present invention, redundant content is omitted to avoid excessive complexity in the description of this specification.
[0109] Another aspect of the present invention comprises a first primer set comprising a forward primer having the nucleotide sequence of SEQ ID NO. 1 and a reverse primer having the nucleotide sequence of SEQ ID NO. 2;
[0110] A second primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 4 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 5;
[0111] A third primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 7 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 8;
[0112] A fourth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 16 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 17; and
[0113] A fifth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 19 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 20;
[0114] The present invention relates to a method for providing information for diagnosing a lumpy skin virus infection, comprising an amplification step of amplifying a target nucleic acid from a sample separated from a specimen using a composition for detecting lumpy skin virus comprising one or more primer sets selected from a group consisting of
[0115] In the present invention, the specimen is a substance collected from a subject for examination, and may be one or more selected from the group consisting of, for example, skin lesions, skin scabs, skin nodules, blood, whole blood, serum, saliva, nasal secretions, oral secretions, and tissue fluid of the subject, but is not limited thereto.
[0116] In the present invention, nasal secretions or oral secretions may be collected using a swab, for example, by inserting a sample collection swab into the nasal cavity or oral cavity of a subject and collecting from the mucous membrane of the inner wall of the nasal cavity or oral cavity, but are not limited thereto.
[0117] In the present invention, the skin lesion may be collected using a disposable biopsy punch, and the blood may be collected in a container containing EDTA (ethylene-diamine-tetraacetic acid), but is not limited thereto.
[0118] In the present invention, the subject may be a bovine.
[0119] In the present invention, the amplification step may be performed using RT-PCR (Reverse transcription polymerase chain reaction), and the RT-PCR may be rRT-PCR (real-time RT-PCR) or qRT-PCR (quantitative RT-PCR), and for example, may be MP rRT-PCR (Multiplex real-time reverse transcription polymerase chain reaction), but is not limited thereto.
[0120] In the present invention, the above composition is
[0121] A first primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 1 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 2; and
[0122] A second primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 4 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 5,
[0123] A third primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 7 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 8,
[0124] A fourth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 16 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 17, and
[0125] A fifth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 19 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 20.
[0126] One or more primer sets selected from the group consisting of; and
[0127] It simultaneously detects Capripoxvirus (CPV) and Lumpy Skin virus.
[0128] In the present invention, the composition may simultaneously detect capripoxvirus (CPV) and lumpy skin virus.
[0129] In the present invention, the caprifox virus may be one or more selected from the group consisting of sheeppox virus (SPPV) and goatpox virus (GTPV).
[0130] In the present invention, the above composition is
[0131] A second primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 4 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 5;
[0132] A third primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 7 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 8;
[0133] A fourth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 16 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 17; and
[0134] A fifth primer set comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO. 19 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 20;
[0135] It includes two or more primer sets selected from the group consisting of,
[0136] Simultaneous differential detection of two or more types selected from a group consisting of field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy Skin Virus.
[0137] In the present invention, the composition may simultaneously detect field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy Skin Virus.
[0138] In the present invention, the composition may additionally include one or more probes selected from the group consisting of a probe with the nucleotide sequence of SEQ ID NO. 3, a probe with the nucleotide sequence of SEQ ID NO. 6, a probe with the nucleotide sequence of SEQ ID NO. 9, a probe with the nucleotide sequence of SEQ ID NO. 18, and a probe with the nucleotide sequence of SEQ ID NO. 21.
[0139] In the present invention, the probe may additionally include a reporter or a quencher.
[0140] Since the method for providing information for diagnosing a lumpy skin virus infection according to the present invention includes a composition for detecting a lumpy skin virus, which is another aspect of the present invention, redundant content is omitted to avoid excessive complexity in the description of this specification. Effects of the invention
[0141] The present invention relates to a kit for detecting Lumpy Skin Virus, wherein, as a result of performing detection from a sample using a first primer set, a second primer set, and a third primer set, Caprifox virus (CPV) and Lumpy Skin Virus (LSDV) can be simultaneously differentiated and diagnosed, and as a result of performing detection from a sample using a second primer set, a third primer set, and a fourth primer set, or using a third primer set, a fourth primer set, and a fifth primer set, field strains, vaccine strains, and vaccine-derived recombinant field strains of Lumpy Skin Virus (LSDV) can be simultaneously differentiated and diagnosed, exhibiting excellent detection sensitivity and excellent detection performance as no non-specific amplification of other viruses of major bovine diseases occurs, so this can be effectively used as a method for providing information for diagnosing Lumpy Skin Virus infection. Brief explanation of the drawing
[0142] FIGS. 1a to 1h are graphs evaluating the analytical sensitivity in standard DNA using CPV / LSDV qPCR Premix (A) according to one embodiment of the present invention. FIGS. 2a to 2p are graphs showing the minimum detection limit in standard DNA that were repeatedly measured and evaluated using CPV / LSDV qPCR Premix (A) according to one embodiment of the present invention. FIGS. 3a to 3d are graphs showing the distribution of Ct values according to standard DNA concentration for CPV, LSDV LW126, LSDV LW011, and Endogenous IPC for CPV / LSDV qPCR Premix (A) according to one embodiment of the present invention. FIGS. 4a to 4d are graphs showing standard curves for Ct values of CPV, LSDV LW126, LSDV LW011, and Endogenous IPC for CPV / LSDV qPCR Premix (A) according to one embodiment of the present invention. FIGS. 5a to 5f are graphs evaluating the analytical sensitivity in standard DNA using an LSDV typing qPCR Premix (B) according to one embodiment of the present invention. FIGS. 6a to 6l are graphs showing the repeated measurement and evaluation of the minimum detection limit in standard DNA using an LSDV typing qPCR Premix (B) according to one embodiment of the present invention. FIGS. 7a to 7c are graphs showing the distribution of Ct values according to standard DNA concentration for LSDV vaccine-derived recombinant field strain, LSDV vaccine strain, and LSDV field strain, respectively, for LSDV typing qPCR Premix (B) according to one embodiment of the present invention. FIGS. 8a to 8c are graphs showing the standard curves for the Ct values of the LSDV vaccine-derived recombinant field strain, LSDV vaccine strain, and LSDV field strain, respectively, for the LSDV typing qPCR Premix (B) according to one embodiment of the present invention. FIGS. 9a to 9f are graphs evaluating the analytical sensitivity in standard DNA using an LSDV typing qPCR Premix (C) according to one embodiment of the present invention. FIGS. 10a to 10l are graphs showing the repeated measurement and evaluation of the minimum detection limit in standard DNA using an LSDV typing qPCR Premix (C) according to one embodiment of the present invention. FIGS. 11a to 11c are graphs showing the distribution of Ct values according to standard DNA concentration for LSDV vaccine-derived recombinant field strain, LSDV vaccine strain, and LSDV field strain, respectively, for LSDV typing qPCR Premix (C) according to one embodiment of the present invention. FIGS. 12a to 12c are graphs showing the standard curves for the Ct values of the LSDV vaccine-derived recombinant field strain, LSDV vaccine strain, and LSDV field strain, respectively, for the LSDV typing qPCR Premix (B) according to one embodiment of the present invention. FIG. 13a is a graph evaluating specificity by confirming whether CPV / LSDV qPCR Premix (A) crosses with BVDV 1 and 16 other viruses, which are major viral disease causative viruses that can infect cattle according to one embodiment of the present invention. FIG. 13b is a graph evaluating the specificity of CPV / LSDV qPCR Premix (A) based on qRT-PCR results for CPV (FAM), LSDV (HEX), Endogenous IPC (CY5), and Exogenous IPC (TxR) according to one embodiment of the present invention. FIG. 14a is a graph evaluating specificity by confirming whether LSDV typing qPCR Premix (B) crosses with BVDV 1 and 16 other viruses, which are major viral disease causative viruses that can infect cattle according to one embodiment of the present invention. FIG. 14b is a graph evaluating the specificity of an LSDV typing qPCR Premix (B) based on qRT-PCR results for an LSDV vaccine-derived recombinant field strain (FAM), an LSDV vaccine strain (HEX), an LSDV field strain (TxR), and an Exogenous IPC (CY5) according to one embodiment of the present invention. FIG. 15a is a graph evaluating specificity by confirming whether LSDV typing qPCR Premix (C) crosses with BVDV 1 and 16 other viruses, which are major viral disease causative viruses that can infect cattle according to one embodiment of the present invention. FIG. 15b is a graph evaluating the specificity of an LSDV typing qPCR Premix (C) based on qRT-PCR results for an LSDV vaccine-derived recombinant field strain (FAM), an LSDV vaccine strain (HEX), an LSDV field strain (TxR), and an Exogenous IPC (CY5) according to one embodiment of the present invention. FIGS. 16a to 16e are graphs evaluating the detection ability of LSDV typing qPCR Premix (C) against negative bovine serum, LSDV kiesling vaccine strain, LSDV vaccine-derived recombinant field strain, LSDV field strain, and Control DNA according to one embodiment of the present invention. Specific details for implementing the invention
[0143] The present invention will be explained in more detail below through the following examples. However, these examples are merely illustrative of the invention, and the scope of the invention is not limited by these examples.
[0144] Throughout this specification, "%" used to indicate the concentration of a particular substance is (weight / weight)% for solid / solid, (weight / volume)% for solid / liquid, and (volume / volume)% for liquid / liquid, unless otherwise noted.
[0146] Preparation Example: Preparation of primer, probe set, and premix for LSDV detection
[0147] The inventors have developed a real-time genetic diagnostic method capable of distinguishing between viruses belonging to the genus Capripoxvirus (CPV) and Lumpy skin disease virus (LSDV), and a real-time genetic diagnostic method capable of simultaneously distinguishing LSDV neethling vaccine strain (LSDV neethling vaccine strain, Cluster 1.1), LSDV classical field strain (LSDV classical field strain, Cluster 1.2), and LSDV vaccine-like recombinant strains (LSDV vaccine-like recombinant strains, Cluster 2.5).
[0149] Preparation Example 1: CPV / LSDV qPCR Premix (A)
[0150] As shown in Table 1 below, the inventors designed and manufactured a primer pair and a probe set for the differential diagnosis of viruses of the Caprifox virus (CPV) genus, such as SPPV (Sheeppox virus) and GTPV (Goatpox virus), and Lumpy Skin Virus (LSDV), and manufactured a qPCR premix containing the same and designated it as CPV / LSDV qPCR Premix (A).
[0151] CPV / LSDV qPCR Premix (A) Target Name Sequence (5'-3') Size(bp) Conc(μM) Sequence number number Capripoxvirus(CPV)(LW068) CAP3F CTGAGYAAGTTACAAAGACATGGA 24 0.2 1 1st Primer Set CAP1R TRTGTGTTCCTGGAGCTGAT 20 0.2 2 CAP1P FAM-ATTGGATGGATGCACAATAGTATATGTTG-BHQ1 29 0.1 3 LSDV(LW011, LW126) SH3003F TTAGTAGCGCCACCATGTATAATAG 25 0.4 4 2nd Primer Set SH3004R GTATTTTCATAAGTTGAAGGCGTTGTAA 28 0.4 5 SH3005P HEX-TGTACTGAGAATTGTGCTAA-MGB 20 0.3 6 LSDV_field_1F TGGGAYGATAACAACGTTTATG 22 0.3 7 3rd Primer Set LSDV_field_1R ACATTGTCATCCGGTAATGTA 21 0.3 8 LSDV_field_1P HEX-TTACCACCTAATGATAGTGTTTATGATTTACC-BHQ1 32 0.2 9 Endogenous IPC(GAPDH) SH2778F ACATGGCCTCCAAGGAGTA 19 0.4 10 6th Primer Set SH2883R TTCTCAGTGTGGCGGAGAT 19 0.4 11 SH2884P Cy5-CAGCAGGAGCACGAGAGGAAG-BHQ2 21 0.3 12 Exogenous IPC SH2914F CCCTGCCGTACAATATCCTTAG 22 0.2 13 7th Primer Set SH2915R CAGCGGCAGAAGGTCCTAT 19 0.2 14 SH2916P TxR-ACAGCCCTGTGGTTGGTATGTCA-BHQ2 23 0.1 15
[0152] - CPV common primer (LSDV LW068 gene): CPV common detection
[0153] - LSDV primer (LSDV LW011 gene, LW126 gene): LSDV common detection
[0154] - Bovine Endogenous IPC primer (GAPDH gene): Detection of bovine-derived samples
[0156] As can be seen in Table 1, CAP3F, CAP1R, and CAP1P, which are primer and probe sets for the LW068 gene of Lumpy Skin Virus (LSDV) to detect viruses of the Caprifox virus (CPV) genus in common, are shown in SEQ ID NOs 1 to 3, respectively.
[0157] SH3003F, SH3004R, and SH3005P, which are primer and probe sets for the LW011 and LW126 genes of Lumpy Skin Virus (LSDV) respectively for common detection of Lumpy Skin Virus (LSDV), and LSDV_field_1F, LSDV_field_1R, and LSDV_field_1P are shown in SEQ ID NOs 4 to 9, respectively.
[0158] SH2778F, SH2883R, and SH2884P, which are bovine endogenous internal positive control primers and probes for detecting bovine-derived samples, are a set of primers and probes for the bovine GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene and are shown in SEQ ID NOs 10 to 12, respectively.
[0159] In addition, exogenous internal positive control (IPC) primers and probes SH2914F, SH2915R, and SH2916P, used to confirm whether the PCR reaction is normal, are shown in SEQ ID NOs 13 to 15, respectively.
[0160] As shown in Table 1 above, each primer and probe set was prepared and mixed according to each concentration (μM) to prepare CPV / LSDV qPCR Premix (A), which is a qPCR premix for real-time genetic diagnosis of differentiation between viruses belonging to the genus Caprifoxavia (CPV) and Lumpy Skin Virus (LSDV).
[0162] Preparation Example 2: LSDV typing qPCR Premix (B)
[0163] As shown in Table 2 below, a set of primers and probes was designed and manufactured to differentiate between the LSDV kiesling vaccine strain, the LSDV field strain, and the LSDV vaccine-derived recombinant field strain, and a qPCR premix containing these was prepared and labeled as LSDV typing qPCR Premix (B).
[0164] LSDV typing qPCR Premix (B) Target Name Sequence (5'-3') Size(bp) Conc(μM) Sequence number number LW011 SH3003F TTAGTAGCGCCACCATGTATAATAG 25 0.4 4 2nd Primer Set SH3004R GTATTTTCATAAGTTGAAGGCGTTGTAA 28 0.4 5 SH3005P FAM-TGTACTGAGAATTGTGCTAA-BHQ1 20 0.3 6 LW126 LSDV_field_1F TGGGAYGATAACAACGTTTATG 22 0.2 7 3rd Primer Set LSDV_field_1R ACATTGTCATCCGGTAATGTA 21 0.2 8 LSDV_field_1P TxR-TTACCACCTAATGATAGTGTTTATGATTTACC-BHQ2 32 0.2 9 LW144 LSDV vac 3F CAACTTTGATGCATCTACCTATACGAT 27 0.3 16 4th Primer Set LSDV vac 2R CCTTCATAGCCTATTCCGAGAG 22 0.3 17 LSDV vac 2P HEX-CACTTGCGTAACTAATTCCACCCA-BHQ1 24 0.2 18 Exogenous IPC SH2914F CCCTGCCGTACAATATCCTTAG 22 0.2 13 7th Primer Set SH2915R CAGCGGCAGAAGGTCCTAT 19 0.2 14 SH2916P Cy5-ACAGCCCTGTGGTTGGTATGTCA-BHQ2 23 0.2 15
[0165] - Common primer (LSDV LW011 gene) for LSDV Kiesling vaccine strain and LSDV vaccine-derived recombinant field strain: Detected in both vaccine strain and vaccine-derived recombinant field strain
[0166] - LSDV Kiesling vaccine strain primer (LSDV LW144 gene): Vaccine strain detection
[0167] - LSDV field strain primer (LSDV LW126 gene): Detection of field strain
[0169] As can be seen in Table 2, SH3003F, SH3004R, and SH3005P, which are primer and probe sets for the LW011 gene of Lumpy Skin Virus (LSDV), were shown in SEQ ID NOs 4 to 6, respectively, to detect both the LSDV kiesling vaccine strain and the LSDV vaccine-derived recombinant field strain.
[0170] For the detection of the LSDV kiesling vaccine strain, LSDV vac 3F, LSDV vac 2R, and LSDV vac 2P, which are primer and probe sets for the LW144 gene of Lumpy Skin Virus (LSDV), were shown in SEQ ID NOs 16 to 18, respectively.
[0171] For the detection of LSDV field strains, LSDV_field_1F, LSDV_field_1R, and LSDV_field_1P, which are primer and probe sets for the LW126 gene of Lumpy Skin Virus (LSDV), were shown in SEQ ID NOs 7 to 9, respectively.
[0172] In addition, SH2914F, SH2915R, and SH2916P, which are Exogenous IPC primer and probe sets for confirming accurate gene amplification, are shown in SEQ ID NOs 13 to 15, respectively.
[0173] As shown in Table 2 above, each primer and probe set was prepared and mixed according to each concentration (μM) to produce LSDV typing qPCR Premix (B), which is a qPCR premix for real-time genetic diagnosis of simultaneous differentiation of LSDV kiesling vaccine strain, LSDV field strain, and LSDV vaccine-derived recombinant field strain.
[0175] Preparation Example 3: LSDV typing qPCR Premix (C)
[0176] As shown in Table 3 below, a set of primers and probes was designed and manufactured to differentiate between the LSDV kiesling vaccine strain, the LSDV field strain, and the LSDV vaccine-derived recombinant field strain, and a qPCR premix containing these was prepared and labeled as LSDV typing qPCR Premix (C).
[0177] LSDV typing qPCR Premix (C) Target Name Sequence (5'-3') Size(bp) Conc(μM) Sequence number number LW126 LSDV_field_1F TGGGAYGATAACAACGTTTATG 22 0.2 7 3rd Primer Set LSDV_field_1R ACATTGTCATCCGGTAATGTA 21 0.2 8 LSDV_field_1P TxR-TTACCACCTAATGATAGTGTTTATGATTTACC-BHQ2 32 0.2 9 LW144 LSDV vac 3F CAACTTTGATGCATCTACCTATACGAT 27 0.3 16 4th Primer Set LSDV vac 2R CCTTCATAGCCTATTCCGAGAG 22 0.3 17 LSDV vac 2P HEX-CACTTGCGTAACTAATTCCACCCA-BHQ1 24 0.2 18 LW133 SH3085F ATGGAATCTGTGCWGAAATAAAGTA 25 0.3 19 5th Primer Set SH3088R AGCCGAAGGGAACGCACTG 19 0.3 20 SH3091P FAM-TCATAAAATAGAGGGATTTGATGAG-MGB 25 0.1 21 Exogenous IPC SH2914F CCCTGCCGTACAATATCCTTAG 22 0.2 13 7th Primer Set SH2915R CAGCGGCAGAAGGTCCTAT 19 0.2 14 SH2916P Cy5-ACAGCCCTGTGGTTGGTATGTCA-BHQ2 23 0.2 15
[0178] - Primer common to LSDV field strain and LSDV vaccine-derived recombinant field strain (LSDV LW133 gene): Detected in both field strain and vaccine-derived recombinant field strain
[0179] - LSDV Kiesling vaccine strain primer (LSDV LW144 gene): Vaccine strain detection
[0180] - LSDV field strain primer (LSDV LW126 gene): Detection of field strain
[0182] As can be seen in Table 3, SH3085F, SH3088R, and SH3091P, which are primer and probe sets for the LW133 gene of Lumpy Skin Virus (LSDV) for detecting both LSDV field strains and LSDV vaccine-derived recombinant field strains, are shown in SEQ ID NOs 19 to 21, respectively.
[0183] LSDV vac 3F, LSDV vac 2R, and LSDV vac 2P, which are primer and probe sets for the LW144 gene of Lumpy Skin Virus (LSDV) for the detection of LSDV kiesling vaccine strains, are shown in SEQ ID NOs 16 to 18, respectively.
[0184] LSDV_field_1F, LSDV_field_1R, and LSDV_field_1P, which are primer and probe sets for the LW126 gene of Lumpy Skin Virus (LSDV) for the detection of LSDV field strains, are shown in SEQ ID NOs 7 to 9, respectively.
[0185] In addition, SH2914F, SH2915R, and SH2916P, which are Exogenous IPC primer and probe sets for confirming accurate gene amplification, are shown in SEQ ID NOs 13 to 15, respectively.
[0186] As shown in Table 3 above, each primer and probe set was prepared and mixed according to each concentration (μM) to produce LSDV typing qPCR Premix (C), which is a qPCR premix for real-time genetic diagnosis of simultaneous differentiation of LSDV kiesling vaccine strain, LSDV field strain, and LSDV vaccine-derived recombinant field strain.
[0188] Example 1: Verification of Sensitivity of Primer and Probe Sets for Target Gene Detection by Premix
[0189] 1-1. Verification of the sensitivity of the primer and probe set for target gene detection in CPV / LSDV qPCR Premix (A)
[0190] 1-1-1. Analytical Sensitivity
[0191] For the CPV / LSDV qPCR Premix (A) of Preparation Example 1, the theoretical (copies / μl) minimum detection limit was evaluated using standard DNA.
[0192] Oligomers of CPV's LW068 gene (76mer), LSDV's LW011 gene (130mer), LW126 gene (113mer), and Endogenous IPC's GAPDH gene (110mer) were synthesized, and three sets of cloning primers were designed as shown in Table 4 below.
[0193] Name Sequence (5'->3') Target gene Size(bp) CAP3F CTGAGYAAGTTACAAAGACATGGA LW068 76 CAP1R TRTGTGTTCCTGGAGCTGAT SH3003F TTAGTAGCGCCACCATGTATAATAG LW011, LW126 130, 113 SH3004R GTATTTTCATAAGTTGAAGGCGTTGTAA SH2778F ACATGGCCTCCAAGGAGTA GAPDH 110 SH2883R TTCTCAGTGTGGCGGAGAT
[0194] PCR was performed using the corresponding oligo set to obtain CPV 76bp, LSDV 130bp, 113bp, and Endogenous IPC 110bp products. These products were then used as inserts to clone them into T-vectors, respectively, using a mini prep kit according to the manufacturer's instructions. The plasmids were extracted using a mini prep kit in accordance with the manufacturer's instructions. The plasmid DNA was quantified and serially diluted 1 / 10 with 1xPBS (Phosphate-buffered saline) to 10 7 , 10 6 , 10 5 , 10 4 , 10 3 , 10 2 , 10 1 , 10 0 Standard samples at a concentration of copies / μl were prepared. qRT-PCR was performed and the Ct (Cycle threshold) value was analyzed, and the results are shown in Table 5 and Figures 1a to 1h.
[0195] No Sample CT value FAM(CPV) HEX(LSDV outdoor stock) HEX (LSDV vaccine-derived recombinant field strain) Cy5(Endogenous IPC) 1 10^7 15.49 17.14 15.01 13.73 2 10^6 18.76 20.10 18.08 16.63 3 10^5 22.11 23.60 21.29 20.29 4 10^4 25.27 26.51 24.67 23.55 5 10^3 28.55 30.02 27.75 26.78 6 10^2 32 32.53 30.68 29.60 7 10^1 35.10 35.43 34.11 34.01 8 10^0 37.8 37.69 37.14 36.53
[0196] As can be seen in Table 5 and Figures 1a to 1h, the analytical sensitivity evaluation of the CPV / LSDV qPCR Premix (A) confirmed that all CPV, LSDV, and Endogenous IPC DNA samples tested simultaneously were detectable at a concentration of 1 copy / μl. Furthermore, it was confirmed that the Ct values for each standard concentration exhibited good linearity (R 2 =0.99, or 1.00).
[0198] 1-1-2. Limit of detection in standard DNA
[0199] For the CPV / LSDV qPCR Premix (A) of Preparation Example 1, the theoretical minimum detection limit for standard DNA was evaluated by repeated measurements at the limit concentration level.
[0200] Oligomers of the LW068 gene of CPV (76mer), the LW011 gene of LSDV (130mer), the LW126 gene (113mer), and the GAPDH gene of Endogenous IPC (110mer) were synthesized, and three types of cloning primers were designed as shown in Table 4 above.
[0201] PCR was performed using the corresponding oligomer set to obtain CPV 76bp, LSDV 130bp, 113bp, and Endogenous IPC 110bp products. These products were then used as inserts to encode into T-vectors, respectively, and cloned. Subsequently, plasmids were extracted using a mini prep kit according to the manufacturer's instructions. The plasmid DNA was quantified and serially diluted 1 / 10 with 1xPBS to 10 1Standard sample mixes at limit concentration levels of , 5, 1, and 0.5 copies / μl were prepared, and 24 tests were repeated for each concentration, and the results are shown in Table 6, Figures 2a to 2p, Figures 3a to 3d, and Figures 4a to 4d.
[0202] division 10copies / μl(50copies / reaction) 5copies / μl(25copies / reaction) 1 copy / μl (5 copies / reaction) 0.5copies / μl(2.5copies / reaction) CPV (FAM) Positives / Number of Tests 24 / 24 24 / 24 23 / 24 20 / 24 CPV (FAM) Detection Rate (%) 100.0% 100.0% 95.8% 83.3% LSDV LW126 Field strain (HEX) positives / tests 24 / 24 24 / 24 24 / 24 20 / 24 LSDV LW126 Outdoor (HEX) Detection Rate (%) 100.0% 100.0% 100% 83.3% LSDV LW011 vaccine-derived recombinant field strain (HEX) positives / tests 24 / 24 24 / 24 24 / 24 21 / 24 Detection rate (%) of LSDV LW011 vaccine-derived recombinant field strain (HEX) 100.0% 100.0% 100% 87.5% Endogenous IPC (Cy5) positivity / Number of tests 24 / 24 24 / 24 24 / 24 20 / 24 Endogenous IPC (Cy5) Detection Rate (%) 100.0% 100.0% 100% 83.3%
[0204] As can be seen in Table 6, Figures 2a to 2p, Figures 3a to 3d, and Figures 4a to 4d, when standard DNA samples at the limit concentration levels of CPV LW068, LSDV LW011, LW126, and Endogenous IPC GAPDH were simultaneously tested, it was confirmed that 100% detection was possible for all samples up to a concentration of 1 copies / μl. The detection rate decreased as the concentration decreased, and since the lowest detection limit is defined as the concentration at which a detection capability of 95% or more of positive results is obtained from repeated measurements, the lowest detection limit of the CPV / LSDV qPCR Premix (A) according to Preparation Example 1 was determined to be 1 copies / μl or less based on the above results.
[0206] 1-2. Verification of the sensitivity of the primer and probe set for target gene detection of LSDV typing qPCR Premix (B)
[0207] 1-2-1. Analytical Sensitivity
[0208] For the LSDV typing qPCR Premix (B) of Preparation Example 2, the theoretical (copies / μl) minimum detection limit was evaluated using standard DNA.
[0209] Oligomers of the LW011 gene 130mer from the LSDV vaccine-derived recombinant field strain and the LW144 gene 111mer from the LSDV Niessling vaccine strain were synthesized, and two types of cloning primers were designed as shown in Table 7 below.
[0210] Name Sequence (5'->3') Target gene Size(bp) SH3003F TTAGTAGCGCCACCATGTATAATAG LW011 130 SH3004R GTATTTTCATAAGTTGAAGGCGTTGTAA LSDV vac 3F CAACTTTGATGCATCTACCTATACGAT LW144 111 LSDV vac 2R CCTTCATAGCCTATTCCGAGAG
[0211] In the case of the LSDV field strain, as shown in Table 8 below, the LSDV field strain-specific sequence within the LW126 gene was synthesized and used as a plasmid.
[0212] No. Separator name Asso.no, Note Sequence number 1 NI-2490 NC003027 LW126 190mer:ATAACGTTTTAGAAAATGGATGTACCACAAATACAGGTGAAGAAAATTTAATTTGGGACGATAACAACGTTTATGATTTACCACCTAATGATAGTGTTTATGATTTACCACCTAACGATTTGAGTTGTAACAACGATTGTGTTTATACATTACCGGATGACAATGTTTCAAACATAGAGGAAAAAATAAC 22
[0213] PCR was performed using the corresponding oligo set to obtain products of 130 bp from the LSDV vaccine-derived recombinant field strain and 111 bp from the LSDV Kiesling vaccine strain. These products were then used as inserts to encode into T-vectors, respectively, and cloned. Subsequently, plasmids were extracted using a mini prep kit according to the manufacturer's instructions. The plasmid DNA was quantified and serially diluted 1 / 10 with 1xPBS to 10 7 , 10 6 , 10 5 , 10 4 , 10 3 , 10 2 , 10 1 , 10 0 Standard samples at a concentration of copies / μl were prepared and used for testing. qRT-PCR was performed and Ct values were analyzed, and the results are shown in Table 9 and Figures 5a to 5f.
[0214] No Sample CT value FAM (LSDV vaccine-derived recombinant field strain) HEX (LSDV Kiesling vaccine) TxR (LSDV outdoor stock) 1 10^7 14.33 16.13 15.20 2 10^6 17.45 19.42 18.39 3 10^5 21.04 22.86 21.58 4 10^4 24.18 26.24 24.37 5 10^3 27.64 30.13 27.73 6 10^2 30.52 33.27 30.75 7 10^1 34.06 35.83 34.03 8 10^0 37.2 38.02 36.75
[0215] As can be seen in Table 9 and Figures 5a to 5f, the results of the analytical sensitivity evaluation of the LSDV typing qPCR Premix (B) according to Preparation Example 2 confirmed that when DNA samples of the respective LSDV vaccine-derived recombinant field strain, LSDV Kiesling vaccine strain, and LSDV field strain were simultaneously tested, all were detectable at a concentration of 1 copies / μl. In addition, it was confirmed that the Ct values for each standard concentration exhibited good linearity (R 2 =0.99, or 1.00).
[0217] 1-2-2. Limit of detection in standard DNA
[0218] For the LSDV typing qPCR Premix (B) of Preparation Example 2, the theoretical minimum detection limit for standard DNA was evaluated by repeated measurements at the limit concentration level.
[0219] Oligomers of the LW011 gene (130mer) from the LSDV vaccine-derived recombinant field strain and the LW144 gene (111mer) from the LSDV Niessling vaccine strain were synthesized, and two types of cloning primers were designed as shown in Table 7 above.
[0220] In the case of the LSDV field strain, as shown in Table 8 above, the LSDV field strain-specific sequence within the LW126 gene was synthesized and used as a plasmid.
[0221] PCR was performed using the corresponding oligo set to obtain products of the LSDV vaccine-derived recombinant field strain (130 bp) and the LSDV Kiesling vaccine strain (111 bp). These products were then used as inserts to encode into T-vectors, respectively, and cloned. Subsequently, plasmids were extracted using a mini prep kit according to the manufacturer's instructions. The plasmid DNA was quantified and serially diluted 1 / 10 with 1xPBS to 10 1 Standard sample mixes at limit concentration levels of , 5, 1, and 0.5 copies / ul were prepared, and 24 tests were repeated for each concentration. The results are shown in Table 10, Figures 6a to 6l, Figures 7a to 7c, and Figures 8a to 8c.
[0222] division 10copies / μl(50copies / reaction) 5copies / μl(25copies / reaction) 1 copy / μl (5 copies / reaction) 0.5copies / μl(2.5copies / reaction) LSDV vaccine-derived recombinant field strain (FAM) positivity / test count 24 / 24 24 / 24 24 / 24 21 / 24 Detection rate (%) of LSDV vaccine-derived recombinant field strain (FAM) 100.0% 100.0% 100% 87.5% LSDV Kiesling Vaccine (HEX) Positives / Tests 24 / 24 24 / 24 24 / 24 21 / 24 LSDV Kiesling Vaccine Strain (HEX) Detection Rate (%) 100.0% 100.0% 100% 87.5% LSDV field strain (TxR) positivity / test count 24 / 24 24 / 24 24 / 24 19 / 24 LSDV Outdoor Track (TxR) Detection Rate (%) 100.0% 100.0% 100% 79.17%
[0224] As can be seen in Table 10, Figs. 6a to 6l, Figs. 7a to 7c, and Figs. 8a to 8c, when standard DNA samples at the limit concentration levels of each LSDV vaccine-derived recombinant field strain LW011, LSDV Kiesling vaccine strain LW144, and LSDV field strain LW126 were simultaneously tested, it was confirmed that all samples were 100% detectable up to a concentration of 1 copies / μl. The detection rate decreased as the concentration decreased, and since the lowest detection limit is defined as the concentration at which a detection capability of 95% or more of positive results is obtained from repeated measurements, the lowest detection limit of the LSDV typing qPCR Premix (B) according to Preparation Example 2 was set to 1 copies / μl or less based on the above results.
[0226] 1-3. Verification of the sensitivity of the primer and probe set for target gene detection in LSDV typing qPCR Premix (C)
[0227] 1-3-1. Analytical Sensitivity
[0228] For the LSDV typing qPCR Premix (C) of Preparation Example 3, the theoretical (copies / μl) minimum detection limit was evaluated using standard DNA.
[0229] An oligomer of the LW144 gene 111mer of the LSDV Niessling vaccine strain was synthesized, and one type of cloning primer was designed as shown in Table 11 below.
[0230] Name Sequence (5'->3') Target gene Size(bp) LSDV vac 3F CAACTTTGATGCATCTACCTATACGAT LW144 111 LSDV vac 2R CCTTCATAGCCTATTCCGAGAG
[0232] In the case of the LSDV vaccine-derived recombinant field strain, as shown in Table 12 below, the common sequence of the LSDV field strain and the LSDV vaccine-derived recombinant field strain within the LW133 gene was synthesized and used as a plasmid.
[0233] No. Separator name Asso.no, Note Sequence number 1 NI-2490 AF325528 LW133 155mer:ATGGAATCTGTGCTGAAATAAAGTACGATGGCGAACGAATTCAAATTCATAAAGACAATAATTTATATAAATATTTTAGTAGAAATCTAAAACCAGTTTTATTTCATAAAATAGAGGGATTTGATGAGTTTCTAACCAGTGGCTTCCCTTCGGCT 23
[0235] In the case of the LSDV field strain, as shown in Table 8 above, the LSDV field strain-specific sequence within the LW126 gene was synthesized and used as a plasmid.
[0236] PCR was performed using the corresponding oligo set to obtain a 111 bp product of the LSDV Kiesling vaccine strain. This product was then used as an insert to be incorporated into T-vectors for cloning, after which the plasmids were extracted using a mini prep kit according to the manufacturer's instructions. The plasmid DNA was quantified and serially diluted 1 / 10 with 1xPBS to 10 7 , 10 6 , 10 5 , 10 4 , 10 3 , 10 2 , 10 1 , 10 0 Standard samples at a concentration of copies / ul were prepared and used for testing. qRT-PCR was performed and Ct values were analyzed, and the results are shown in Table 13 and Figures 9a to 9f.
[0237] No Sample CT value FAM (LSDV vaccine-derived recombinant field strain) HEX (LSDV Kiesling vaccine) TxR (LSDV outdoor stock) 1 10^7 14.29 14.13 15.44 2 10^6 17.62 17.96 18.35 3 10^5 21.37 21.22 21.01 4 10^4 24.55 24.83 24.31 5 10^3 27.84 28.47 27.24 6 10^2 31.09 31.92 30.95 7 10^1 34.16 34.18 33.82 8 10^0 37.12 37.56 37.64
[0238] As can be seen in Table 13 and Figures 9a to 9f, the analytical sensitivity evaluation of the LSDV typing qPCR Premix (C) confirmed that all samples of the LSDV vaccine-derived recombinant field strain, LSDV Kiesling vaccine strain, and LSDV field strain DNA, when tested simultaneously, were detectable at a concentration of 1 copies / μl. Furthermore, it was confirmed that the Ct values for each standard concentration exhibited good linearity (R 2 =0.99).
[0240] 1-3-2. Limit of detection in standard DNA
[0241] For the LSDV typing qPCR Premix (C) of Preparation Example 3, the theoretical minimum detection limit for standard DNA was evaluated by repeated measurements at the limit concentration level.
[0242] An oligomer of the LW144 gene 111mer of the LSDV Kiesling vaccine strain was synthesized, and one type of cloning primer was designed as shown in Table 11 above.
[0243] In the case of the LSDV vaccine-derived recombinant field strain, as shown in Table 12 above, the common sequence of the LSDV Niessling field strain and the LSDV vaccine-derived recombinant field strain within the LW133 gene was synthesized and used as a plasmid.
[0244] In the case of the LSDV field strain, as shown in Table 8 above, the LSDV field strain-specific sequence within the LW126 gene was synthesized and used as a plasmid.
[0245] PCR was performed using the corresponding oligo set to obtain a 111 bp product of the LSDV Kiesling vaccine strain. This product was then used as an insert to be incorporated into T-vectors for cloning, after which the plasmids were extracted using a mini prep kit according to the manufacturer's instructions. The plasmid DNA was quantified and serially diluted 1 / 10 with 1xPBS to 10 1 Standard sample mixes at limit concentration levels of , 5, 1, and 0.5 copies / ul were prepared, and 24 tests were repeated for each concentration, and the results are shown in Table 14, Figures 10a to 10l, Figures 11a to 11c, and Figures 12a to 12c.
[0246] division 10copies / μl(50copies / reaction) 5copies / μl(25copies / reaction) 1 copy / μl (5 copies / reaction) 0.5copies / μl(2.5copies / reaction) LSDV vaccine-derived recombinant field strain (FAM) positivity / test count 24 / 24 24 / 24 24 / 24 20 / 24 Detection rate (%) of LSDV vaccine-derived recombinant field strain (FAM) 100.0% 100.0% 100% 83.3% LSDV Kiesling Vaccine (HEX) Positives / Tests 24 / 24 24 / 24 24 / 24 23 / 24 LSDV Kiesling Vaccine Strain (HEX) Detection Rate (%) 100.0% 100.0% 100% 95.83% LSDV field strain (TxR) positivity / test count 24 / 24 24 / 24 24 / 24 20 / 24 LSDV Outdoor Track (TxR) Detection Rate (%) 100.0% 100.0% 100% 83.3%
[0247] As shown in Table 14, Figs. 10a to 10l, Figs. 11a to 11c, and Figs. 12a to 12c, when standard DNA samples at the limit concentration levels of each LSDV vaccine-derived recombinant field strain LW133, LSDV Kiesling vaccine strain LW144, and LSDV field strain LW126 were simultaneously tested, it was confirmed that all samples were 100% detectable up to a concentration of 1 copies / μl. The detection rate decreased as the concentration decreased, and since the lowest detection limit is defined as the concentration at which a detection capability of 95% or more of positive results is obtained from repeated measurements, the lowest detection limit of the LSDV typing qPCR Premix (C) according to Preparation Example 3 was determined to be 1 copies / μl or less based on the above results.
[0249] Example 2: Verification of the specificity of a primer and probe set for LSDV detection
[0250] 2-1. Verification of the Specificity of CPV / LSDV qPCR Premix (A)
[0251] To verify the specificity of the CPV / LSDV qPCR Premix (A) of Preparation Example 1, a specificity evaluation was conducted for similar viral diseases. Major viral disease causative viruses that can infect cattle were established as shown in Table 15 below, and cross-reference with the CPV / LSDV qPCR Premix (A) of Preparation Example 1 was confirmed using these viruses. Target sequences within the target genes of LW068 (CPV), LW011 (LSDV), and LW126 (LSDV) were synthesized, and each plasmid was diluted to a constant concentration of 1 pg / ul and used as a positive control. The results are shown in Table 15, Figure 13a, and Figure 13b.
[0252] No Name Strain Results 1 Bovine viral diarrhea virus 1 (BVDV1) VR00000053(NADL) voice 2 Bovine viral diarrhea virus 2 (BVDV2) KVCC-VR1100008(08Q723) voice 3 Bovine coronavirus (BCV) - voice 4 Bovine rotavirus VR-1290 voice 5 Akabane Virus - voice 6 Ibaraki Virus - voice 7 Infectious Bovine Rhinotracheitis Virus (IBRV) - voice 8 Chuzan Virus - voice 9 Aino Virus - voice 10 Sheeppox virus (SPPV) NVRL-CPV-SP-NA-001 Mongolia CPV (FAM) positive 11 Goatpox virus (GTPV) NVRL-CPV-GP-NA-001 Oman CPV (FAM) positive 12 Lumpy skin disease virus (LSDV) NVRL-CPV-LS-NA-001 Neethling pox CPV (FAM), LSDV (HEX) positive 13 Bovine Leukemia Virus (BLV) BLV infected FLK cell (foreign import) voice 14 Peste des petits ruminants virus type 1 (PPRV I) Ivory Coast / 1989 voice 15 Peste des petits ruminants virus type 2 (PPRV II) Nigeria / 1975 / 2 voice 16 Peste des petits ruminants virus type 3 (PPRV III) Ibri / 1983 voice 17 Pestodes ruminants virus type 4 (PPRV IV) Georgia / Tbilisi / 2016 voice 18 Positive Control 22.11(FAM) 23.60(HEX)20.29(Cy5) 21.15(TxR)
[0254] As can be seen in Table 15, Figs. 13a and 13b, the CPV / LSDV qPCR Premix (A) of Preparation Example 1 is It was confirmed that there was no cross-reactivity with viruses of major bovine diseases, and positive results were confirmed for the Positive Control, CPV, and LSDV. Furthermore, while only FAM fluorescence was detected for SPPV and GTPV, which are viruses of the Caprifoxavian (CPV) genus, both FAM and HEX fluorescence were detected for LSDV, confirming the simultaneous detection of CPV viruses and LSDV.
[0256] 2-2. Verification of the specificity of LSDV typing qPCR Premix (B)
[0257] To verify the specificity of the LSDV typing qPCR Premix (B) according to Preparation Example 2, a specificity evaluation for similar viral diseases was conducted. Major viral diseases that can infect cattle were causative viruses as shown in Table 16 below, and cross-reference with the LSDV typing qPCR Premix (B) of Preparation Example 2 was confirmed using these viruses. Target sequences within the target genes of LW011 (LSDV), LW144 (LSDV), and LW126 (LSDV) were synthesized, and each plasmid was diluted to a constant concentration of 1 pg / ul and used as a positive control. The results are shown in Table 16, Figure 14a, and Figure 14b.
[0258] No Name Strain Results 1 Bovine viral diarrhea virus 1 (BVDV1) VR00000053(NADL) voice 2 Bovine viral diarrhea virus 2 (BVDV2) KVCC-VR1100008(08Q723) voice 3 Bovine coronavirus (BCV) - voice 4 Bovine rotavirus VR-1290 voice 5 Akabane Virus - voice 6 Ibaraki Virus - voice 7 Infectious Bovine Rhinotracheitis Virus (IBRV) - voice 8 Chuzan Virus - voice 9 Aino Virus - voice 10 Sheeppox virus (SPPV) NVRL-CPV-SP-NA-001 Mongolia voice 11 Goatpox virus (GTPV) NVRL-CPV-GP-NA-001 Oman voice 12 Lumpy skin disease virus (LSDV) NVRL-CPV-LS-NA-001 Neethling pox LSDV vaccine-derived field strain (FAM), LSDV kiesling vaccine strain (HEX) positive 13 Bovine Leukemia Virus (BLV) BLV infected FLK cell (foreign import) voice 14 Peste des petits ruminants virus type 1 (PPRV I) Ivory Coast / 1989 voice 15 Peste des petits ruminants virus type 2 (PPRV II) Nigeria / 1975 / 2 voice 16 Peste des petits ruminants virus type 3 (PPRV III) Ibri / 1983 voice 17 Pestodes ruminants virus type 4 (PPRV IV) Georgia / Tbilisi / 2016 voice 18 Positive Control 22.11(FAM) 23.60(HEX)20.29(Cy5) 21.15(TxR)
[0260] As can be seen in Table 16, Figure 14a, and Figure 14b, it was confirmed that the LSDV typing qPCR Premix (B) of Preparation Example 2 had no cross-reactivity with viruses of major bovine diseases, and positive results were confirmed for the Positive Control, the LSDV vaccine-derived recombinant field strain, and the LSDV kiesling vaccine strain.
[0262] 2-3. Verification of the specificity of LSDV typing qPCR Premix (C)
[0263] To verify the specificity of the LSDV typing qPCR Premix (C) according to Preparation Example 3, a specificity evaluation for similar viral diseases was conducted. Major viral diseases that can infect cattle were causative viruses as shown in Table 17 below, and cross-reference with the LSDV typing qPCR Premix (C) of Preparation Example 3 was confirmed using these viruses. Target sequences within the target genes of LW133 (LSDV), LW144 (LSDV), and LW126 (LSDV) were synthesized, and each plasmid was diluted to a constant concentration of 1 pg / ul and used as a positive control. The results are shown in Table 17, Figure 15a, and Figure 15b.
[0264] No Name Strain Results 1 Bovine viral diarrhea virus 1 (BVDV1) VR00000053(NADL) voice 2 Bovine viral diarrhea virus 2 (BVDV2) KVCC-VR1100008(08Q723) voice 3 Bovine coronavirus (BCV) - voice 4 Bovine rotavirus VR-1290 voice 5 Akabane Virus - voice 6 Ibaraki Viruw - voice 7 Infectious Bovine Rhinotracheitis Virus (IBRV) - voice 8 Chuzan Virus - voice 9 Aino Virus - voice 10 Sheeppox virus (SPPV) NVRL-CPV-SP-NA-001 Mongolia voice 11 Goatpox virus (GTPV) NVRL-CPV-GP-NA-001 Oman voice 12 Lumpy skin disease virus (LSDV) NVRL-CPV-LS-NA-001 Neethling pox LSDV Kiesling vaccine strain (HEX) positive 13 Bovine Leukemia Virus (BLV) BLV infected FLK cell (foreign import) voice 14 Peste des petits ruminants virus type 1 (PPRV I) Ivory Coast / 1989 voice 15 Peste des petits ruminants virus type 2 (PPRV II) Nigeria / 1975 / 2 voice 16 Peste des petits ruminants virus type 3 (PPRV III) Ibri / 1983 voice 17 Pestodes ruminants virus type 4 (PPRV IV) Georgia / Tbilisi / 2016 voice 18 Positive Control 22.11(FAM) 23.60(HEX)20.29(Cy5) 21.15(TxR)
[0266] As can be seen in Table 17, Figure 15a and Figure 15b, the LSDV typing qPCR Premix (C) of Preparation Example 3 was confirmed to have no cross-reactivity with viruses of major bovine diseases, and both the Positive Control and the LSDV kiesling vaccine strain were confirmed to be positive.
[0268] Example 3: Sensitivity Evaluation Test Data
[0269] 3-1. Evaluation of Sensitivity of CPV / LSDV qPCR Premix (A) and LSDV typing qPCR Premix (B) in Positive Standard Samples Held by the Animal and Plant Quarantine Agency
[0270] To evaluate clinical sensitivity, the prototype CPV / LSDV qPCR Premix (A) and LSDV typing qPCR Premix (B) kits were evaluated using nucleic acids from the LSDV Kiesling vaccine strain, LSDV field strain, and LSDV vaccine-derived recombinant field strain obtained from the Pirbright Institute by the Animal and Plant Quarantine Agency. The results are shown in Tables 18 and 19 below.
[0271] As shown in Tables 18 and 19 below, experiments were conducted on the LSDV vaccine-derived recombinant field strain, LSDV Kiesling vaccine strain, and LSDV field strain using the CPV / LSDV qPCR Premix (A) of Preparation Example 1. The results confirmed that CPV (FAM), LSDV (HEX), and Exogenous IPC (TxR) fluorescence were all positive, and no nonspecificity was observed (in the case of Endogenous IPC (Cy5), detection in positive samples is not a mandatory condition).
[0272] In addition, as shown in Tables 18 and 19 below, experiments were conducted on the LSDV vaccine-derived recombinant field strain, LSDV kiesling vaccine strain, and LSDV field strain using the LSDV typing qPCR Premix (B) of Preparation Example 2. As a result, the LSDV vaccine-derived recombinant field strain (FAM), LSDV kiesling vaccine strain (HEX), LSDV field strain (TxR), and Exogenous IPC (Cy5) were all confirmed to be positive, and no non-specificity was observed.
[0273] Pirbright Institute Distribution of LSDV Kiesling Vaccine and LSDV Field Strain Results division CPV / LSDV qPCR Premix (A) LSDV typing qPCR Premix (B) CPV LSDV Endo IPC Exo IPC LSDV vaccine-derived recombinant field strain LSDV Kiesling vaccine LSDV outdoor vehicle Exo IPC FAM HEX Cy5 TxR FAM HEX TxR Cy5 LSDV Kiesling vaccine Neethling 10^-1 21.40 22.96 N / A 22.43 22.12 22.01 N / A 21.67 Neethling 10^-2 24.89 26.15 N / A 22.45 25.42 25.33 N / A 21.52 Neethling 10^-3 28.23 29.72 N / A 22.92 28.87 28.78 N / A 21.55 Neethling 10^-4 31.73 33.29 N / A 22.60 32.65 32.43 N / A 21.70 Neethling 10^-5 35.59 37.14 N / A 22.65 36.59 36.37 N / A 21.66 Neethling 10^-6 N / A N / A N / A 22.64 N / A 39.54 N / A 21.67 Neethling 10^-7 N / A N / A N / A 22.86 N / A N / A N / A 21.59 Neethling 10^-8 N / A N / A N / A 22.58 N / A N / A N / A 21.53 LSDV outdoor vehicle 1993 10^-1 20.62 21.61 N / A 22.46 N / A N / A 20.28 22.07 1993 10^-2 24.15 25.15 N / A 22.72 N / A N / A 23.55 21.58 1993 10^-3 27.51 28.65 N / A 22.87 N / A N / A 27.02 21.47 1993 10^-4 30.82 32.16 N / A 22.95 N / A N / A 30.40 21.63 1993 10^-5 34.19 36.04 N / A 22.83 N / A N / A 34.74 21.67 1993 10^-6 N / A N / A N / A 22.80 N / A N / A N / A 21.70 1993 10^-7 N / A N / A N / A 22.81 N / A N / A N / A 21.66 1993 10^-8 N / A N / A N / A 22.80 N / A N / A N / A 21.57 LSDV outdoor vehicle 2007 10^-1 21.67 22.94 N / A 22.49 N / A N / A 21.22 22.10 2007 10^-2 25.01 26.11 N / A 22.75 N / A N / A 24.66 21.85 2007 10^-3 28.40 29.76 N / A 23.07 N / A N / A 28.12 21.77 2007 10^-4 31.56 32.73 N / A 22.94 N / A N / A 31.21 21.91 2007 10^-5 34.47 35.83 N / A 22.86 N / A N / A 34.59 21.76 2007 10^-6 N / A N / A N / A 22.85 N / A N / A N / A 21.83 2007 10^-7 N / A N / A N / A 22.85 N / A N / A N / A 21.76 2007 10^-8 N / A N / A N / A 22.78 N / A N / A N / A 21.55 LSDV outdoor vehicle 2018 10^-1 23.23 24.33 N / A 22.59 N / A N / A 22.92 21.97 2018 10^-2 26.43 27.58 N / A 22.59 N / A N / A 26.11 21.67 2018 10^-3 30.09 31.21 N / A 22.82 N / A N / A 29.70 21.82 2018 10^-4 33.27 35.30 N / A 22.92 N / A N / A 32.90 21.72 2018 10^-5 38.07 38.54 N / A 22.82 N / A N / A 37.03 21.65 2018 10^-6 N / A N / A N / A 22.84 N / A N / A N / A 21.80 2018 10^-7 N / A N / A N / A 23.21 N / A N / A N / A 21.63 2018 10^-8 N / A N / A N / A 22.42 N / A N / A N / A 21.61
[0274] Endo IPC: Endogenous IPC, Exo IPC: Exogenous IPC
[0275] Pirbright Institute distribution of LSDV vaccine-derived recombinant field strain results division CPV / LSDV qPCR Premix (A) LSDV typing qPCR Premix (B) CPV LSDV Endo IPC Exo IPC LSDV vaccine-derived recombinant outdoor vaccine LSDV Kiesling vaccine LSDV outdoor vehicle Exo IPC FAM HEX Cy5 TxR FAM HEX TxR Cy5 LSDV vaccine-derived recombinant field strain 032 A 10^-1 22.35 23.17 N / A 23.11 22.60 N / A N / A 23.08 032 A 10^-2 25.67 26.55 N / A 23.42 26.05 N / A N / A 23.17 032 A 10^-3 29.09 30.11 N / A 23.62 29.39 N / A N / A 23.22 032 A 10^-4 32.33 33.46 N / A 23.70 32.70 N / A N / A 23.25 032 A 10^-5 36.09 36.39 N / A 23.54 35.58 N / A N / A 23.18 032 A 10^-6 38.78 N / A N / A 23.71 N / A N / A N / A 23.34 032 A 10^-7 N / A N / A N / A 23.57 N / A N / A N / A 23.42 032 A 10^-8 N / A N / A N / A 23.58 N / A N / A N / A 23.18 LSDV vaccine-derived recombinant field strain 027 A 10^-1 22.37 23.30 N / A 23.10 22.76 N / A N / A 23.10 027 A 10^-2 25.77 26.61 N / A 23.31 26.02 N / A N / A 23.15 027 A 10^-3 29.06 30.18 N / A 23.46 29.38 N / A N / A 23.31 027 A 10^-4 32.51 33.65 N / A 23.50 33.01 N / A N / A 23.31 027 A 10^-5 35.99 37.52 N / A 23.52 36.08 N / A N / A 23.21 027 A 10^-6 N / A N / A N / A 23.59 N / A N / A N / A 23.25 027 A 10^-7 N / A N / A N / A 23.63 N / A N / A N / A 23.33 027 A 10^-8 N / A N / A N / A 23.31 N / A N / A N / A 23.09
[0277] From the above results, it was confirmed that when using the CPV / LSDV qPCR Premix of Preparation Example 1 (A) and the LSDV typing qPCR Premix of Preparation Example 2 (B) according to the present invention, the field strain, vaccine strain, and vaccine-derived recombinant field strain of LSDV can be simultaneously differentiated and diagnosed with high sensitivity and specificity in a single qPCR reaction.
[0278] 3-2. Evaluation of Detectability of LSDV-typing qPCR Premix (C)
[0279] To evaluate detection capability, the prototype LSDV typing qPCR Premix (C) kit was evaluated using nucleic acids from the LSDV Kiesling vaccine strain, LSDV field strain, and LSDV vaccine-derived recombinant field strain obtained from the Pirbright Institute by the Animal and Plant Quarantine Agency. qPCR was performed by repeating the reaction cycle for 40 cycles: 5 minutes at 25°C, 10 minutes at 95°C, 5 seconds at 95°C, and 30 seconds at 58°C. Target sequences within the target genes of LW133 (LSDV), LW144 (LSDV), and LW126 (LSDV) were synthesized, and each plasmid was diluted to a constant concentration of 1 pg / ul to be used as control DNA 1 and 2. The results are shown in Table 20 and Figures 16a to 16e.
[0280] As can be seen in Table 20 and Figures 16a to 16e, when experiments were conducted on the LSDV kiesling vaccine strain, LSDV field strain, and LSDV vaccine-derived recombinant field strain using the LSDV typing qPCR Premix (C) of Preparation Example 3, the LSDV vaccine-derived recombinant field strain (FAM), LSDV kiesling vaccine strain (HEX), LSDV field strain (TxR), and Exogenous IPC (Cy5) fluorescence were all confirmed to be positive, and no non-specificity was observed.
[0281] Sample LSDV vaccine-derived recombinant outdoor vaccine LSDV Kiesling vaccine LSDV outdoor vehicle Exo IPC FAM HEX TxR Cy5 Negative bovine serum 1 N / A N / A N / A 22.06 Negative bovine serum 2 N / A N / A N / A 21.55 Negative bovine serum 3 N / A N / A N / A 21.52 Negative bovine serum 4 N / A N / A N / A 21.36 Negative bovine serum 5 N / A N / A N / A 21.46 Negative bovine serum 6 N / A N / A N / A 21.39 Negative bovine serum 7 N / A N / A N / A 21.37 Negative bovine serum 8 N / A N / A N / A 21.4 LSDV Kiesling vaccine 10 -2 N / A 22.82 N / A 21.38 LSDV Kiesling vaccine 10 -3 N / A 26.65 N / A 21.33 LSDV Kiesling vaccine 10 -4 N / A 29.77 N / A 21.25 LSDV vaccine-derived recombinant field strain 10 -2 24.23 N / A N / A 21.27 LSDV vaccine-derived recombinant field strain 10 -3 27.28 N / A N / A 21.2 LSDV vaccine-derived recombinant field strain 10 -4 30.76 N / A N / A 21.22 LSDV vaccine-derived recombinant field inoculation 10 -5 34.95 N / A N / A 21.32 LSDV Outdoor Run (1993) 10 -3 29.13 N / A 29.2 21.46 LSDV Outdoor Run (2007) 10 -3 29.49 N / A 29.55 21.33 LSDV Outdoor Run (2018) 10 -3 29.64 N / A 29.71 21.29 Control DNA 1 20.88 22.91 23.01 21.61 Control DNA 2 20.83 22.93 22.98 21.49
[0283] From the above results, it was confirmed that when using the LSDV typing qPCR Premix (C) of Preparation Example 3 according to the present invention, the field strain, vaccine strain, and vaccine-derived recombinant field strain of LSDV can be simultaneously differentiated and diagnosed with high sensitivity and specificity in a single qRT-PCR reaction.
[0284] In addition, when there is a co-infection with the vaccine strain and the vaccine-derived recombinant field strain, the LSDV typing qPCR Premix of Preparation Example 2 (B) cannot distinguish between them, but the LSDV typing qPCR Premix of Preparation Example 3 (C) can distinguish between the vaccine strain and the vaccine-derived recombinant field strain even when there is a co-infection, so it can be usefully applied to distinguish breakthrough infection with the vaccine-derived recombinant field strain in vaccinated individuals.
Claims
Claim 1 A composition for detecting Lumpy skin disease virus (LSDV) comprising: a primer set comprising a first primer set comprising a forward primer having the nucleotide sequence of SEQ ID NO. 1 and a reverse primer having the nucleotide sequence of SEQ ID NO. 2; a second primer set comprising a forward primer having the nucleotide sequence of SEQ ID NO. 4 and a reverse primer having the nucleotide sequence of SEQ ID NO. 5; and a third primer set comprising a forward primer having the nucleotide sequence of SEQ ID NO. 7 and a reverse primer having the nucleotide sequence of SEQ ID NO. 8; and additionally comprising a probe having the nucleotide sequence of SEQ ID NO. 3; a probe having the nucleotide sequence of SEQ ID NO. 6; and a probe having the nucleotide sequence of SEQ ID NO.
9. Claim 2 A composition for detecting Lumpy Skin Virus comprising: a primer set comprising a second primer set comprising a forward primer having the nucleotide sequence of SEQ ID NO. 4 and a reverse primer having the nucleotide sequence of SEQ ID NO. 5; a third primer set comprising a forward primer having the nucleotide sequence of SEQ ID NO. 7 and a reverse primer having the nucleotide sequence of SEQ ID NO. 8; and a fourth primer set comprising a forward primer having the nucleotide sequence of SEQ ID NO. 16 and a reverse primer having the nucleotide sequence of SEQ ID NO. 17; and additionally comprising a probe having the nucleotide sequence of SEQ ID NO. 6; a probe having the nucleotide sequence of SEQ ID NO. 9; and a probe having the nucleotide sequence of SEQ ID NO.
18. Claim 3 A composition for detecting Lumpy Skin Virus, comprising: a primer set comprising a third primer set comprising a forward primer having the nucleotide sequence of SEQ ID NO. 7 and a reverse primer having the nucleotide sequence of SEQ ID NO. 8; a fourth primer set comprising a forward primer having the nucleotide sequence of SEQ ID NO. 16 and a reverse primer having the nucleotide sequence of SEQ ID NO. 17; and a fifth primer set comprising a forward primer having the nucleotide sequence of SEQ ID NO. 19 and a reverse primer having the nucleotide sequence of SEQ ID NO. 20; and additionally comprising a probe having the nucleotide sequence of SEQ ID NO. 9; a probe having the nucleotide sequence of SEQ ID NO. 18; and a probe having the nucleotide sequence of SEQ ID NO.
21. Claim 4 A composition for detecting Lumpy Skin Virus according to any one of claims 1 to 3, wherein the probe additionally comprises a reporter or a quencher. Claim 5 A kit for detecting Lumpy skin disease virus (LSDV) comprising: a primer set comprising a first primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 1 and a reverse primer with a nucleotide sequence of SEQ ID NO. 2; a second primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 4 and a reverse primer with a nucleotide sequence of SEQ ID NO. 5; and a third primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 7 and a reverse primer with a nucleotide sequence of SEQ ID NO. 8; and additionally comprising a probe with a nucleotide sequence of SEQ ID NO. 3; a probe with a nucleotide sequence of SEQ ID NO. 6; and a probe with a nucleotide sequence of SEQ ID NO.
9. Claim 6 A kit for detecting Lumpy Skin Virus comprising: a primer set comprising a second primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 4 and a reverse primer with a nucleotide sequence of SEQ ID NO. 5; a third primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 7 and a reverse primer with a nucleotide sequence of SEQ ID NO. 8; and a fourth primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 16 and a reverse primer with a nucleotide sequence of SEQ ID NO. 17; and additionally comprising a probe with a nucleotide sequence of SEQ ID NO. 6; a probe with a nucleotide sequence of SEQ ID NO. 9; and a probe with a nucleotide sequence of SEQ ID NO.
18. Claim 7 A kit for detecting Lumpy Skin Virus, comprising: a primer set comprising a third primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 7 and a reverse primer with a nucleotide sequence of SEQ ID NO. 8; a fourth primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 16 and a reverse primer with a nucleotide sequence of SEQ ID NO. 17; and a fifth primer set comprising a forward primer with a nucleotide sequence of SEQ ID NO. 19 and a reverse primer with a nucleotide sequence of SEQ ID NO. 20; and additionally comprising a probe with a nucleotide sequence of SEQ ID NO. 9; a probe with a nucleotide sequence of SEQ ID NO. 18; and a probe with a nucleotide sequence of SEQ ID NO.
21. Claim 8 A kit for detecting Lumpy Skin virus, wherein, in any one of claims 5 to 7, the probe additionally comprises a reporter or a quencher. Claim 9 A method for providing information for diagnosing Lumpy Skin Virus (LSDV) infection, comprising a primer set comprising: a first primer set comprising a forward primer comprising a nucleotide sequence of SEQ ID NO. 1 and a reverse primer comprising a nucleotide sequence of SEQ ID NO. 2; a second primer set comprising a forward primer comprising a nucleotide sequence of SEQ ID NO. 4 and a reverse primer comprising a nucleotide sequence of SEQ ID NO. 5; and a third primer set comprising a forward primer comprising a nucleotide sequence of SEQ ID NO. 7 and a reverse primer comprising a nucleotide sequence of SEQ ID NO. 8; and additionally comprising a probe comprising a nucleotide sequence of SEQ ID NO. 3; a probe comprising a nucleotide sequence of SEQ ID NO. 6; and a probe comprising a nucleotide sequence of SEQ ID NO. 9, wherein the composition comprises an amplification step for amplifying a target nucleic acid from a sample isolated from a specimen. Claim 10 A method for providing information for diagnosing a lumpy skin virus infection, comprising a primer set comprising: a second primer set comprising a forward primer comprising a nucleotide sequence of SEQ ID NO. 4 and a reverse primer comprising a nucleotide sequence of SEQ ID NO. 5; a third primer set comprising a forward primer comprising a nucleotide sequence of SEQ ID NO. 7 and a reverse primer comprising a nucleotide sequence of SEQ ID NO. 8; and a fourth primer set comprising a forward primer comprising a nucleotide sequence of SEQ ID NO. 16 and a reverse primer comprising a nucleotide sequence of SEQ ID NO. 17; and additionally comprising a probe comprising a nucleotide sequence of SEQ ID NO. 6; a probe comprising a nucleotide sequence of SEQ ID NO. 9; and a probe comprising a nucleotide sequence of SEQ ID NO. 18, wherein the composition for detecting lumpy skin virus comprises an amplification step for amplifying a target nucleic acid separated from a specimen. Claim 11 A method for providing information for diagnosing a lumpy skin virus infection, comprising an amplification step of amplifying a target nucleic acid from a sample separated from a specimen using a composition for detecting lumpy skin virus, wherein the composition further comprises: a third primer set including a forward primer consisting of the nucleotide sequence of SEQ ID NO. 7 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 8; a fourth primer set including a forward primer consisting of the nucleotide sequence of SEQ ID NO. 16 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 17; a fifth primer set including a forward primer consisting of the nucleotide sequence of SEQ ID NO. 19 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO. 20; a probe consisting of the nucleotide sequence of SEQ ID NO. 9; a probe consisting of the nucleotide sequence of SEQ ID NO. 18; and a probe consisting of the nucleotide sequence of SEQ ID NO.
21. Claim 12 A method for providing information for diagnosing a lumpy skin virus infection, wherein, in any one of claims 9 to 11, the probe additionally comprises a reporter or a quencher. Claim 13 delete Claim 14 delete Claim 15 delete Claim 16 delete Claim 17 delete Claim 18 delete
